Microprofit Biotech Highlights Kidney Health on World Kidney Day 2026
Microprofit Biotech Highlights Kidney Health on World Kidney Day 2026
Shenzhen, China – March 12, 2026 – In celebration of World Kidney Day 2026, themed “Kidney Health for All: Caring for People, Protecting the Planet,” Microprofit Biotech emphasizes its commitment to advancing kidney health through cutting-edge in vitro diagnostic (IVD) solutions.
Chronic Kidney Disease: A Global Health Challenge
Chronic Kidney Disease (CKD) affects more than 850 million people worldwide, yet many cases remain undiagnosed due to the silent progression of the disease. Early detection is critical for preventing complications and improving patient outcomes. By leveraging advanced diagnostics and POCT technologies, healthcare providers can screen patients efficiently and identify early kidney dysfunction.
Microprofit Biotech’s fluorecare® Solutions for Early Detection
Microprofit Biotech offers fluorecare® POCT assays, including Microalbumin (MAU) and Cystatin C tests, designed for fast, accurate kidney screening in both laboratory and point-of-care settings. These assays enable the early detection of CKD and other kidney-related conditions, helping clinicians take timely action to improve patient care.
“Our mission is to enhance global kidney health through reliable IVD and POCT solutions,” said a Microprofit Biotech spokesperson. “By providing access to efficient diagnostic testing, we empower healthcare providers to detect kidney dysfunction early and contribute to more sustainable healthcare systems.”
Promoting Kidney Health Awareness
On this World Kidney Day, Microprofit Biotech encourages healthcare providers, laboratories, and individuals to prioritize kidney health through regular screening, timely monitoring, and early intervention. Early detection of CKD is key to reducing the global burden of kidney disease and supporting better patient outcomes.
